Human Placental-Derived Stem Cell Transplantation (HPDSC) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01586455

Human Placental-Derived Stem Cell Transplantation (HPDSC)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.

Status: 
Recruiting
Study Date: 
Mon, 04/01/2013 to Sat, 12/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Human Placental Derived Stem Cell Infusions of thawed HPDSC to be given following UCB infusion. Other Name: HPDSC